Vivani Medical Spearheads Progress in Weight Management Solutions
LIBERATE-1, the first-in-human application of Vivani’s NanoPortal implant technology, has showcased positive safety and efficacy profiles, successfully achieving its main objectives
The preclinical data for the new NPM-139 (semaglutide implant) have revealed an impressive weight loss of about 20%, sustained for more than 6 months with just a single implant, reinforcing the potential for annual dosing
Based on these outcomes, Vivani Medical is poised to prioritize the development of NPM-139, anticipating the commencement of clinical trials as regulatory approvals are secured. This transition reflects the company's commitment to innovative weight management therapies.
Vivani Medical, Inc. (Nasdaq: VANI) is a clinical-stage biopharmaceutical firm focusing on the development of miniature, ultra long-acting drug implants. The company recently disclosed results from its LIBERATE-1 clinical study, which represents the inaugural human testing of the NPM-115 implant, utilizing its proprietary NanoPortal™ technology.
Vivani also shared new preclinical findings for the NPM-139 (semaglutide implant) from a continuing study, affirming the prioritization of this semaglutide implant in the company's development pipeline. Semaglutide serves as the active agent in popular drugs such as Ozempic, Wegovy, and Rybelsus.
According to Vivani's Chief Executive Officer, Adam Mendelsohn, Ph.D., the results from the LIBERATE-1 study with overweight and obese subjects were promising. He expressed satisfaction with the study's achievement of primary objectives, enhancing confidence in future development stages.
The revelation of the new preclinical feasibility data for the NPM-139 underscores the impressive performance of this treatment candidate. Results show sustained weight loss of about 20% following a single administration lasting over six months, indicating a potential pathway towards annual dosing. This decision to advance NPM-139 is bolstered by several compelling factors.
Highlights from LIBERATE-1 Study Results
The LIBERATE-1 Phase 1 trial successfully met its core objectives, mainly assessing the safety and tolerability of the NPM-115 implant while examining its pharmacokinetic (PK) profile over a span of 9 weeks. The study findings demonstrated that the implant was generally well-tolerated, with no significant gastrointestinal adverse effects experienced by subjects throughout its duration.
Moreover, the study yielded critical insights into the implant's drug release characteristics, which highlighted its potential for providing sustained delivery of medication over extended periods. The positive release profile further supports the durability of this implant technology for both the NPM-115 and the NPM-139 candidates.
Semaglutide Implant: Advancements in Preclinical Feasibility
In ongoing preclinical studies, significant milestones have been reached regarding the development of the semaglutide implant, NPM-139. This research supports the initial ideal for a bi-annual dosing schedule, with the company remaining optimistic about achieving annual dosing capabilities in the near future.
Vivani's short-term focus centers on optimizing pharmacokinetic parameters and preparing for the timely submission of an Investigational New Drug application for NPM-139, a crucial step in advancing this promising candidate.
About Vivani Medical, Inc.
Employing its unique NanoPortal™ platform, Vivani Medical creates biopharmaceutical implants designed to deliver drugs reliably and sustainably. Their leading product, NPM-139, is a miniature GLP-1 (semaglutide) implant being developed to aid in the management of chronic weight issues for obese and overweight individuals, all while displaying potential for annual dosing. Vivani's portfolio also includes the NPM-115 exenatide implant, targeted at chronic weight management, alongside the NPM-119 program for type-2 diabetes treatment.
This innovative approach aims to tackle medication compliance challenges, providing patients an easier method of receiving treatment compared to traditional oral and injectable options. This initiative is critical, considering that approximately half of patients fail to adhere to prescribed medication regimens.
Frequently Asked Questions
What is the focus of Vivani Medical?
Vivani Medical is dedicated to developing innovative miniature drug implants, primarily targeting chronic weight management and other health conditions.
What is NPM-139?
NPM-139 is Vivani Medical's semaglutide implant designed for weight management, showing promising results for sustained weight loss with potential annual dosing.
How did the LIBERATE-1 study perform?
The LIBERATE-1 Phase 1 study successfully met its primary objectives regarding the safety and tolerability of the NPM-115 implant, showing favorable results.
When can we expect the clinical development for NPM-139 to begin?
While clinical development for NPM-139 is anticipated to start pending regulatory approvals, specific timelines have not been disclosed.
How does Vivani's technology address medication adherence?
Vivani's implants aim to enhance medication adherence by providing long-lasting drug delivery and minimizing the need for daily or weekly treatments.
